Copyright
©The Author(s) 2024.
World J Gastrointest Pharmacol Ther. May 28, 2024; 15(3): 90757
Published online May 28, 2024. doi: 10.4292/wjgpt.v15.i3.90757
Published online May 28, 2024. doi: 10.4292/wjgpt.v15.i3.90757
Table 3 Symptom relief at weeks 2 and 4 of GASTRAP® DIRECT treatment
| Symptom relief | W2 (%) | W4 (%) |
| Abdominal pain | ||
| Unchanged | 42 | 34 |
| Relief (very much, considerable) | 58 (53, 5) | 66 (48, 18) |
| Bloating | ||
| Unchanged | 48 | 33 |
| Relief (very much, considerable) | 52 (45, 7) | 67 (49, 18) |
| Abdominal distension | ||
| Unchanged | 55 | 43 |
| Relief (very much, considerable) | 45 (33, 12) | 57 (40, 17) |
| Impact of global symptoms on daily life | ||
| Unchanged | 37 | 23 |
| Relief (very much, considerable) | 63 (42, 21) | 77 (53, 24) |
| Flatulence | ||
| Unchanged | 46 | 44 |
| Relief (very much, considerable) | 54 (44, 10) | 56 (41, 15) |
- Citation: Talbodec N, Le Roy P, Fournier P, Lesage B, Lepoutre E, Castex F, Godchaux JM, Vandeville L, Bismuth B, Lesage X, Bayart P, Genin M, Rousseaux C, Maquet V, Modica S, Desreumaux P, Valibouze C. Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study. World J Gastrointest Pharmacol Ther 2024; 15(3): 90757
- URL: https://www.wjgnet.com/2150-5349/full/v15/i3/90757.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v15.i3.90757